Jane Street Group LLC Purchases Shares of 48,812 Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Jane Street Group LLC bought a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 48,812 shares of the company's stock, valued at approximately $83,000. Jane Street Group LLC owned about 0.12% of Vigil Neuroscience as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after purchasing an additional 19,436 shares during the period. Northern Trust Corp raised its stake in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after acquiring an additional 14,572 shares during the period. Boothbay Fund Management LLC purchased a new stake in Vigil Neuroscience in the 4th quarter worth about $249,000. Marshall Wace LLP lifted its stake in Vigil Neuroscience by 85.3% in the fourth quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock worth $454,000 after purchasing an additional 122,853 shares during the last quarter. Finally, Blair William & Co. IL purchased a new stake in shares of Vigil Neuroscience in the fourth quarter worth approximately $551,000. Institutional investors own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on VIGL shares. William Blair lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Mizuho downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Stifel Nicolaus cut Vigil Neuroscience from a "buy" rating to a "hold" rating and reduced their price target for the stock from $11.00 to $8.00 in a report on Wednesday, May 28th. Wedbush lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and lowered their price target for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. Finally, Guggenheim set a $8.00 price target on shares of Vigil Neuroscience and gave the company a "neutral" rating in a research report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Price Performance

NASDAQ:VIGL traded up $0.01 during mid-day trading on Thursday, reaching $7.87. The company's stock had a trading volume of 3,582,895 shares, compared to its average volume of 703,991. The stock has a market cap of $367.31 million, a P/E ratio of -3.82 and a beta of 3.43. The company's fifty day simple moving average is $3.78 and its two-hundred day simple moving average is $2.71. Vigil Neuroscience, Inc. has a twelve month low of $1.31 and a twelve month high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. Sell-side analysts expect that Vigil Neuroscience, Inc. will post -2.07 EPS for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.